Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2022 | CheckMate 648: Novel treatment for patients with advanced esophageal squamous cell carcinoma

Hisato Kawakami, MD, PhD, Kindai University, Osaka, Japan, talks on the Phase III CheckMate 648 (NCT03143153) trial, in which the efficacy of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin was compared to fluorouracil plus cisplatin only in patients with unresectable advanced, recurrent or metastatic previously-untreated esophageal squamous cell carcinoma. Dr Kawakami comments on the several factors which were associated with a delayed therapeutic onset of treatment with nivolumab plus ipilimumab, including age and alcohol use, and the implications of this. Moreover, the Glasgow Prognostic Score (GPS) and its association with the efficacy of nivolumab plus ipilimumab is discussed. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.

Disclosures

Honoraria(lecture fee) from: BMS K.K., ONO Pharmaceutical Co., LTD., Taiho Pharmaceutical Co., Ltd., and Daiichi Sankyo, Co., Ltd.
Grant/Research funding from: BMS K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Kobayashi Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co., Ltd., and Daiichi Sankyo, Co., Ltd.